Related references
Note: Only part of the references are listed.Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Elisabetta Patorno et al.
DIABETES OBESITY & METABOLISM (2022)
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study
Seung Jin Han et al.
DIABETES OBESITY & METABOLISM (2021)
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
Subodh Verma et al.
ESC HEART FAILURE (2021)
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
Yutaka Seino et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2021)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka et al.
Lancet Diabetes & Endocrinology (2020)
Reporting and variability of constructing medication treatment episodes in pharmacoepidemiology studies: A methodologic systematic review using the case study ofDPP-4 inhibitors and cardiovascular outcomes
Alanna Weisman et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Kristian B. Filion et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Elisabetta Patorno et al.
CIRCULATION (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
Vinay Garg et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
Mikhail Kosiborod et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
Thomas R. Einarson et al.
VALUE IN HEALTH (2018)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Frederik Persson et al.
DIABETES OBESITY & METABOLISM (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Kare I. Birkeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013
Yu Mi Kang et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
Harindra Rajasekeran et al.
KIDNEY INTERNATIONAL (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians
William H. Shrank et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2011)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
